Case Reports
Journal Article
Add like
Add dislike
Add to saved papers

Treatment of grey zone lymphoma using the R-CODOX-M/R-IVAC protocol: Two case reports.

Medicine (Baltimore) 2017 September
RATIONALE: We report our experience with 2 patients diagnosed with grey zone lymphoma (GZL). The histopathological characteristics of lymphomatous tissues in these patients ranged between those of diffuse large B-cell lymphoma (DLBCL) and the classical Hodgkin lymphoma.

PATIENT CONCERNS: A 52-year-old female presented to the hospital with a history of lower abdominal pain of metastatic origin for 2 days. She was diagnosed with acute appendicitis and had undergone emergency surgery. A 17-year-old male was admitted to the hospital because of acute left upper abdomen pain.

DIAGNOSES: Both patients are diagnosed of GZL primarily based on histopathology.

INTERVENTIONS: Both patients were treated with R-CODOX-M/R-IVAC regimen for 4 to 6 cycles.

OUTCOMES: The short-term curative effect was complete response; no recurrence was observed as of 32-month follow-up.

LESSONS: R-CODOX-M/IVAC regimen exhibited relatively good curative effect. International Prognostic Index score and lactate dehydrogenase level may correlate with prognosis of these patients.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app